Niowave has broken ground on a $75M actinium-225 production facility in Lansing, MI, according to AuntMinnie. It is the company’s 2nd dedicated production site in the city.
The site will include multiple proprietary superconducting linear accelerators, processing systems, and quality systems to support scalable Ac-225 production. Construction is being led by the Christman Company in collaboration with Colliers Engineering & Design, with completion expected in 2028.
Ac-225 is an alpha-emitting isotope used in targeted cancer therapies. Niowave describes Ac-225 as a radioisotope used in treatments designed to selectively destroy cancer cells while limiting damage to surrounding healthy tissue.
Niowave said the new facility is expected to create about 70 jobs. The Lansing-based company has signed major Ac-225 supply agreements with AstraZeneca and Novartis in recent months.
In February, Niowave said its Novartis agreement would support expanded production capacity and that it intended to begin construction of a new Lansing manufacturing facility in early 2026. The company said the agreement would provide Novartis with scalable Ac-225 supply for its radioligand therapy portfolio.
Niowave’s 20-year company update said its 2026 facility plans included 6 accelerators and radiochemistry systems, with Ac-225 production capacity beyond 175 Ci per year. The company said it employs about 180 people and operates facilities in Lansing.
Company:Niowave
Niowave coverage
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
